



European Directorate for the  
Quality of Medicines & HealthCare



## European Pharmacopoeia Commission Secretariat

RZ/PH/2011-05762L  
CV/lke

Strasbourg, 21 September 2011

### CIRCULAR LETTER FOR THE ATTENTION OF THE LIAISON SECTIONS OF THE EUROPEAN PHARMACOPOEIA


Subject: Resolution AP-CPH (11) 7

In accordance with the decision taken by the Public Health Committee (Partial Agreement) (CD-P-SP) at its meeting on 1 December 1994\* and the proposal of the European Pharmacopoeia Commission on 29 June 2011, please find enclosed:

- Resolution AP-CPH (11) 7 concerning the suppression on **1 July 2012** in the European Pharmacopoeia of the following:

Chlorothiazide (0385)	Methaqualone (0510)
Dienestrol (0483)	Methylatropine bromide (0511)
Emetine hydrochloride heptahydrate (0080)	Methylatropine nitrate (0512)
Etofylline (0492)	Physostigmine sulphate (0684)
Hexobarbital (0183)	Succinylsulfathiazole (357)
Histamine phosphate (0144)	Sulfisomidine (639)
Iotalamic acid (0751)	Tubocurarine chloride (0305)

Please contact me if you need further information.



Mrs Cathie VIELLE  
Secretary to the Commission

cc: National Authorities

*\* Note: Following the decisions taken by the Committee of Ministers at its 1017th meeting, on 6 February 2008, pursuant to which the European Committee on pharmaceuticals and pharmaceutical care (CD-P-PH) would carry out the tasks of the Public Health Committee set out in the Convention on the Elaboration of a European Pharmacopoeia (ETS No. 50), as amended by the Protocol (ETS No. 134), and any reference to the "Public Health Committee" in the said Convention and Protocol should from this date be understood as referring to the European Committee on pharmaceuticals and pharmaceutical care.*

Address: 7 Allée Kastner, CS 30026  
F – 67081 Strasbourg (France)  
Tél : +33 (0) 3 88 41 21 83 - Fax: +33 (0) 3 88 41 27 71 – e-mail: Cathie.Vielle@edqm.eu  
Internet address: <http://www.edqm.eu>